For the year ending 2025-12-31, YBGJ had $1,047 increase in cash & cash equivalents over the period.
| Cash Flow | 2025-12-31 |
|---|---|
| Net loss | 1,187,939 |
| Depreciation and amortization | 177,773 |
| Loss on obsolescence inventory | 0 |
| Receivables | -26,941 |
| Prepaid expense | 12,898 |
| Inventory | -12,919 |
| Due from related parties | 0 |
| Lease security deposit | 101,190 |
| Accounts payable and accrued expenses | 22,896 |
| Advances from prospective customers/distributors | 16,316 |
| Net cash used in operating activities | -842,802 |
| Proceeds for sale of equipment | 0 |
| Net cash provided in investing activities | 0 |
| Advances from related parties (net) | 849,545 |
| Capital contributions to subsidiary | 0 |
| Net cash provided by financing activities | 849,545 |
| Effect of exchange rate changes | -5,696 |
| Net increase (decrease) in cash | 1,047 |
| Cash at beginning of period | 7,015 |
| Cash at end of period | 8,062 |
Yubo International Biotech Ltd (YBGJ)
Yubo International Biotech Ltd (YBGJ)